Table 4. Comparison of comorbidity at follow-up of four years between SG and RYGB groups.

*Significance P value < 0.05; **high significance P value < 0.01

Items	SG (n = 50)	RYGB (n = 50)	p value
DM type 2
Comorbidity present at baseline	10 (20%)	13 (26%)	0.32
No difference	6 (12%)	4 (8%)
Resolution	0 (0%)	5 (10%)
Partial resolution	2 (4%)	3 (6%)
Worse	2 (4%)	1 (2%)
HT
Comorbidity present at baseline	16 (32%)	10 (20%)	0.13
No difference	7 (14%)	1 (2%)
Resolution	2 (4%)	7 (14%)
Partial resolution	5 (10%)	2 (4%)
Worse	2 (4%)	2 (4%)
DL
Comorbidity present at baseline	10 (20%)	4 (8%)	0.07
No difference	4 (8%)	4 (8%)
Resolution	1 (2%)	2 (4%)
Partial resolution	1 (2%)	1 (2%)
Worse	4 (8%)	1 (2%)
Joint pain
Comorbidity present at baseline	20 (40%)	15 (30%)	0.20
No difference	7 (14%)	4 (8%)
Resolution	4 (8%)	3 (6%)
Partial resolution	2 (4%)	7 (14%)
Worse	7 (14%)	1 (2%)
GERD
Comorbidity present at baseline	2 (4%)	5 (10%)	0.22
No difference	2 (4%)	2 (4%)
Resolution	1 (2%)	2 (4%)
Partial resolution	1 (2%)	1 (2%)
Worse	1 (2%)	1 (2%)
OSAS
Comorbidity present at baseline	9 (18%)	8 (16%)	0.50
No difference	2 (4%)	3 (6%)
Resolution	1 (2%)	2 (4%)
Partial resolution	6 (12%)	2 (4%)
Worse	1 (2%)	1 (2%)